Now is the time - 2024 will be an extremely busy and hopefully exciting year for the Company. We had a busy end of the year with the closing of study 0205 and the analysis of the very positive data in children, but 2024 will be another interesting year with some major milestones.
We will highlight the main milestones in this update. Thanks for reading!

1: Focus on US launch

  • The US partnership with Ventis Pharma will be one of our main priorities in 2024 initiating, the early access program.
  • A tech transfer of analytical methods has been completed, and sterilized vials and pumps as well as APIs are now available - production will start at the end of this month.
  • More details during Q1 with first sales expected in Q2.

2: Finalize study 0202

  • All approvals from authorities are in place for study 0202 to be initiated at the clinical sites. Final contracts and IMP shipment will take place during Q1.
  • Study 0202 is the remaining safety study in children and will run in selected countries in Europe. We expect recruitment to end during 2H of 2024.
3: Build European partnership
  • The European market is important for our future setup. We initiated the search for a partner in 2023 and have made very good progress. We aim to have an agreement in place during 2024.
  • Ideally, we want a partnership structure that can capture the opportunities of CT002 and potential other assets. CT002 will be initiated once this is in place.

Pipeline update

On 12 September we announced the endorsement by EMA of the PIP for CT002...
In the third quarter of 2023 we announced the agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children. See more details in the link below.

Cessatech management team



Management, Board of Directors and other Insiders.
Together currently hold 16%
Studies show that off label use of medication is the rule rather than the exception and that 79% of the emergency rooms in Scandinavia use physical restraint on children.
Cessatech aims to meet that need – and the first product and lead asset, CT001, is a nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures.
Drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a good effect can be documented. Thus offering economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile.